• President Trump signs executive order mandating drug price parity with other developed nations
  • Pharmaceutical companies face pressure to offer lowest available prices directly to consumers
  • Government explores federal website distribution channel, threatening traditional drug supply chain

Executive Action on Drug Pricing

President Donald Trump signed an executive order on May 12, 2025, that seeks to ensure Americans pay no more than the lowest price available in other comparable countries for prescription drugs. The "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients" order represents the administration's most aggressive move yet to address what it describes as "global freeloading" in pharmaceutical pricing.

The administration has already notified major pharmaceutical companies—including Pfizer and Johnson & Johnson—of new expectations that they offer their best prices to Medicaid patients and refrain from offering better prices to other developed nations than to the United States. According to people familiar with the matter, manufacturers are being encouraged to bypass traditional intermediaries and sell drugs directly to consumers at the Most-Favored-Nation price.

Disrupting Traditional Distribution

A government website is being explored as a potential distribution mechanism to facilitate this goal, according to administration officials who spoke on condition of anonymity. This approach would represent a fundamental shift in how prescription drugs reach American consumers and could significantly disrupt the pharmacy benefit manager industry.

"The current system has allowed other countries to pay significantly less for the same drugs developed with American innovation," one administration official said. "This executive order formalizes our position that this imbalance must end."

The move comes as U.S. patients continue to pay more than three times what patients in other advanced economies pay for brand-name drugs, despite the United States accounting for less than 5% of the world's population but providing about 75% of global pharmaceutical profits.

Industry Response and Implications

Pharmaceutical manufacturers now face the threat of direct government competition if they don't voluntarily reduce prices. Industry representatives have been meeting with administration officials throughout the week, though neither side would comment on the specifics of those discussions when reached for comment.

Legal challenges are expected from manufacturers concerned about trade policy implications and patent rights. The administration's approach leverages U.S. trade policy, envisioning a scenario where expanded foreign revenues for U.S. manufacturers must directly result in lower domestic prices.

For American consumers, especially those reliant on expensive medications, access to lower prices through a potential government portal could mean improved medication adherence and lower out-of-pocket expenses. However, the proposal faces significant implementation hurdles and likely opposition from multiple stakeholders in the healthcare ecosystem.

Correction: An earlier version of this article misstated the percentage of global pharmaceutical profits attributed to the U.S. market. The correct figure is approximately 75%.